DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for intermediate coronary syndrome — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntermediate coronary syndrome maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intermediate coronary syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
A 1965 letter reports that clinical coronary disease is associated with an abnormally increased adhesion-aggregation tendency of blood platelets, measured by Hellem’s method, which the author suggests might indicate an increased tendency to thrombosis. The letter proposes that linolenic acid, found in vegetable oils such as soy bean oil and linseed oil, might reduce this adhesion-aggregation tendency. No patient data, survival figures, or response rates are given; the claim rests on unpublished experiments and references to rat studies of venous thrombosis.
A 2022 review states that the best therapeutic strategy for chronic coronary syndrome remains controversial. It notes that many older randomised trials used medical treatment that is no longer contemporary, because they predated the large-scale use of statins, antiplatelet agents, anti-diabetic drugs with cardiovascular protection, and lifestyle changes with well-established goals. The review asserts that medical treatment is the only therapeutic option capable of reducing atherosclerotic damage and preventing disease progression, but provides no new trial data, patient numbers, or survival outcomes.
A 2025 review of secondary prevention after myocardial infarction states that management of acute coronary syndrome has advanced, with strategies shown to improve survival and reduce cardiovascular adverse events. It describes an expanding body of literature supporting both pharmacologic and non-pharmacologic approaches after acute myocardial infarction, and focuses on recent guidelines and their application in Canadian healthcare. No concrete numbers for survival, response rates, or sample sizes are reported.
What is still missing is any randomised controlled trial testing linolenic acid against modern medical therapy in patients with intermediate coronary syndrome, with hard endpoints such as mortality or myocardial infarction. The 1965 letter provides no patient-level data. The 2022 and 2025 reviews summarise existing knowledge but do not supply new evidence for the specific question of drug repurposing. No trial design, patient stratification strategy, or funding commitment for such a study is described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Internal Medicine · 1965 · 10 citations
LINOLENIC ACID AND CORONARY THROMBOSIS
AbstractLetters and Comments1 December 1965LINOLENIC ACID AND CORONARY THROMBOSISP. A. OWREN, M.D.P. A. OWREN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-6-1160 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: At The American College of Physicians' meeting in Chicago (1) in March this year I reported on experiments indicating that linolenic acid might reduce the tendency to secondary thrombosis in atherosclerotic disease by reducing the adhesion-aggregation tendency of the blood platelets. This suggestion was based on the following findings:1. Clinical coronary disease is associated with an abnormally increased adhesion-aggregation tendency of the blood platelets as measured by Hellem's method. This might mean an increased tendency to thrombosis.2. The intake of vegetable oils with high contents of linolenic acid (soy bean oil, linseed oil) and of...References1. OWREN PA: Coronary thrombosis: its mechanism and possible prevention by linolenic acid. Ann. Intern. Med. 63: 167, 1965. LinkGoogle Scholar2. NORDØY A: The influence of saturated fats, cholesterol, corn oil and linseed oil on experimental venous thrombosis in rats. Thromb. Diath. Haemorrh. 13: 244, 1965. MedlineGoogle Scholar3. NORDØY A: Ibid., p. 543. Google Scholar4. BORCHGREVINKBERGSKAGASKJAEGGESTADSTORMORKEN CFKJE#H Unpublished. Google Scholar5. By a research committee. Google Scholar6. KERRPIRRIEMACAULAYBRONTE-STEWART JWRIB: Platelet-aggregation by phospholipids and free fatty acids. Lancet 1: 1296, 1965. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University Hospital (Rikshospitalet) Oslo, Norway PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByBiological Effects of Alpha-Linolenic AcidHeart AttackFlaxseed, Fiber, and Coronary Heart DiseaseDietary linolenic acid and carotid atherosclerosis: the National Heart, Lung, and Blood Institute Family Heart StudyThe protective effects of dietary fish oil on focal cerebral infarctionInhibition of prostaglandin biosynthesis by eicosapentaenoic acidBiological activities of and requirements for polyunsaturated acids 1 December 1965Volume 63, Issue 6Page: 1160-1161KeywordsBloodOilsPlateletsStable coronary artery diseaseThrombosis Issue Published: 1 December 1965 PDF DownloadLoading ...
International Journal of Cardiovascular Sciences · 2022 · 1 citations · open access
Chronic Coronary Syndrome: Medical Therapy or Myocardial Revascularization?
AbstractThe best therapeutic strategy for chronic coronary syndrome (CCS) is still controversial. The lack of contemporaneity of medical treatment in many randomized clinical trials prior to the large-scale use of statins, antiplatelet agents, anti-diabetic drugs with cardiovascular protection, and changes in life habits with well-established goals limits the applicability of such studies in current clinical practice. Medical treatment is the only therapeutic option capable of reducing atherosclerotic damage and, therefore, of acting effectively in preventing the progression of this [...]
Canadian Cardiology Today · 2025 · 0 citations · open access
Secondary Prevention After Myocardial Infarction: Bridging Evidence to Practice
AbstractManagement of acute coronary syndrome (ACS) has advanced significantly over the past years, with various strategies shown to improve patient survival and reduce cardiovascular (CV) adverse events. An expanding body of literature supports the efficacy of both pharmacologic and non-pharmacologic approaches after acute myocardial infarction (MI). This review aims to provide a comprehensive overview of the secondary prevention strategies after acute MI in the modern era, with a particular focus on recent guidelines and their application in Canadian healthcare practice.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
